Study #2024-0349
A phase III, randomized, open-label, multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic non-small cell lung cancer
MD Anderson Study Status
Enrolling
Treatment Agent
Divarasib, Sotorasib, Adagrasib
Description
The purpose of this study is to assess the safety and efficacy of divarasib compared to locally approved KRAS G12C inhibitors (sotorasib or adagrasib) in participants with KRAS G12C-positive (KRAS G12C +) advanced or metastatic non-small cell lung cancer (NSCLC).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
Study phase:
Phase III
Physician name:
Ferdinandos Skoulidis
Department:
Thoracic/Head & Neck Medical Oncology
For general questions about clinical trials:
1-866-419-2881
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.